Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Haryana cohort of the A1chieve study
| Autor: | Sandeep Suri, Sanjay Kalra, Sameer Aggarwal, Lokesh Garg |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2013 |
| Předmět: |
medicine.medical_specialty
Insulin Analogue endocrine system diseases type 2 diabetes mellitus Endocrinology Diabetes and Metabolism medicine.medical_treatment A1chieve study insulin analogues Type 2 diabetes lcsh:Diseases of the endocrine glands. Clinical endocrinology Insulin aspart Endocrinology A 1 chieve study Internal medicine medicine lcsh:RC799-869 Haryana Insulin detemir lcsh:RC648-665 business.industry Insulin Type 2 Diabetes Mellitus nutritional and metabolic diseases medicine.disease Biphasic insulin aspart Cohort lcsh:Diseases of the digestive system. Gastroenterology Original Article business hormones hormone substitutes and hormone antagonists medicine.drug |
| Zdroj: | Indian Journal of Endocrinology and Metabolism Indian Journal of Endocrinology and Metabolism, Vol 17, Iss 8, Pp 538-541 (2013) |
| ISSN: | 2230-9500 2230-8210 |
| Popis: | Background: The A 1 chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care across four continents. Materials and Methods: Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled from Haryana, India. Results: A total of 345 patients were enrolled in the study. Four different insulin analogue regimens were used in the study. Patients had started on or were switched to biphasic insulin aspart (n = 236), insulin detemir (n = 66), insulin aspart (n = 28), basal insulin plus insulin aspart (n = 1) and other insulin combinations (n = 14). At baseline glycaemic control was poor for both insulin naïve (mean HbA 1 c: 10.7%) and insulin user (mean HbA 1 c: 10.5%) groups. After 24 weeks of treatment, both the groups showed improvement in HbA 1 c (insulin naïve: −3.9%, insulin users: −3.3%). SADRs including major hypoglycaemic events or episodes did not occur in any of the study patients. Conclusion: Starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|